Desjardins Global Asset Management Inc. Gilead Sciences, Inc. Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 28,072 shares of GILD stock, worth $1.87 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
28,072
Previous 28,166
0.33%
Holding current value
$1.87 Million
Previous $2.11 Million
7.77%
% of portfolio
0.25%
Previous 0.23%
Shares
9 transactions
Others Institutions Holding GILD
# of Institutions
1,885Shares Held
1BCall Options Held
8.71MPut Options Held
8.02M-
Black Rock Inc. New York, NY123MShares$8.16 Billion0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$7.64 Billion0.17% of portfolio
-
Capital World Investors Los Angeles, CA84.5MShares$5.63 Billion1.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.2MShares$4.08 Billion1.05% of portfolio
-
State Street Corp Boston, MA57.7MShares$3.84 Billion0.19% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $83.5B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...